SCHEMBL357546

SCHEMBL357546

CC(=O)N1C(=O)c2ccccc2S1(=O)=O

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.64
TSHR P16473 1/20 0.64
CA9 Q16790 8/20 0.59
CA12 O43570 7/20 0.59
CA2 P00918 6/20 0.59
FBP1 P09467 6/20 0.57
ELANE P08246 2/20 0.55
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CYP1A2 P05177 1/20 0.54
MAPT P10636 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
HSD17B10 Q99714 1/20 0.54
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23699755 0.85 CYP2D6 (0.68) CYP2D6TSHRCA9CA12CA2
SCHEMBL7781184 0.84 CYP2D6 (0.66) CYP2D6TSHRCA9CA12CA2
SCHEMBL11287638 0.82 CYP2D6 (0.64) CYP2D6TSHRCA9CA12CA2
SCHEMBL10656285 0.81 FBP1 (0.64) CYP2D6TSHRCA9CA12CA2
SCHEMBL19848646 0.81 CYP2D6 (0.59) CYP2D6TSHRCA9CA12CA2
SCHEMBL9678250 0.81 CYP2D6 (0.59) CYP2D6TSHRCA9CA12CA2
SCHEMBL11443197 0.81 CYP2D6 (0.59) CYP2D6TSHRCA9CA12CA2
SCHEMBL9967796 0.81 CYP2D6 (0.59) CYP2D6TSHRCA9CA12CA2
SCHEMBL12606536 0.81 KDM4E (0.52) CYP2D6TSHRCA9CA12CA2
SCHEMBL12646984 0.81 FBP1 (0.62) CYP2D6TSHRCA9CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009016648-A2 PROCESS FOR THE PREPARATION OF ROCURONIUM BROMIDE AND INTERMEDIATE THEREOF GLAND PHARMA LIMITED (IN) 2009-02-05 WO claimed
JP-61158926-A None JP disclosed
US-11752242-B2 Medical devices, systems, and methods utilizing antithrombin-heparin composition ATH THERAPEUTICS INC. (US) 2023-09-12 US disclosed
CN-114207122-A Mutant PGLB oligosaccharyl transferases 葛兰素史克生物有限公司 2022-03-18 CN disclosed
US-20190030066-A1 ANTITHROMBIN-HEPARIN COMPOSITIONS AND METHODS ATTWILL Medical Solutions, Inc. (CA) 2019-01-31 US disclosed
US-20180177924-A1 Medical Devices, Systems, and Methods Utilizing Antithrombin-Heparin Composition ATTWILL Medical Solution Inc. (CA) 2018-06-28 US disclosed
US-20170020911-A1 ANTITHROMBIN-HEPARIN COMPOSITIONS AND METHODS ATTWILL MEDICAL SOLUTIONS INC. (CA) 2017-01-26 US disclosed
WO-2016201202-A1 MEDICAL DEVICES, SYSTEMS, AND METHODS UTILIZING ANTITHROMBIN-HEPARIN COMPOSITIONS ATTWILL MEDICAL SOLUTIONS INC. (CA) 2016-12-15 WO disclosed
WO-2016168710-A1 ANTITHROMBIN-HEPARIN COMPOSITIONS AND METHODS ATTWILL MEDICAL SOLUTIONS INC. (CA) 2016-10-20 WO disclosed
CN-103328400-B Glass fiber bundling agent and glass fiber reinforced crystalline resin composition ADEKA CORP. (JP) 2015-12-02 CN disclosed
US-6562781-B1 Covalent conjugate composition comprising glycosaminoglycans linked by covalent linkages to a species comprising at least one primary amino group HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT INC. (CA) 2003-05-13 US disclosed
US-6491965-B1 COVALENT LINKAGES COMPRISING AN ALPHA CARBONYL AMINE FORMED BY A AMADORI REARRANGEMENT OF AN IMINE RESULTING FROM REACTION BETWEEN SAID AMINO GROUP OF ANTITHROMBIN AND TERMINAL ALDOSE RESIDUE OF HEPARIN HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC. (CA) 2002-12-10 US disclosed
US-5985815-A Bleach activators WARWICK INTERNATIONAL GROUP LIMITED (GB) 1999-11-16 US disclosed
EP-0863768-A2 GLYCOSAMINOGLYCAN-ANTITHROMBIN III/HEPARIN COFACTOR II CONJUGATES HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC. (CA) 1998-09-16 EP disclosed
EP-0730632-B1 BLEACH ACTIVATORS WARWICK INT GROUP (GB) 1998-03-18 EP disclosed
WO-1997019701-A2 GLYCOSAMINOGLYCAN-ANTITHROMBIN III/HEPARIN COFACTOR II CONJUGATES HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC. (CA) 1997-06-05 WO disclosed
EP-0730632-A1 BLEACH ACTIVATORS Warwick International Group Limited (GB) 1996-09-11 EP disclosed
WO-1995014760-A1 BLEACH ACTIVATORS WARWICK INTERNATIONAL GROUP LIMITED (GB) 1995-06-01 WO disclosed
JP-S61158926-A CARCINOSTATIC AGENT CONTAINING POLYSACCHARIDE SEIKO EPSON CORP 1986-07-18 JP disclosed
US-3990983-A CHLORINATED TRISODIUM PHOSPHATE, TRISODIUM CARBOXYMETHYLOXYSUCCINATE, SODIUM SULFATE, SODIUM SILICATE LEVER BROTHERS COMPANY (US) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11752242-B2 Medical devices, systems, and methods utilizing antithrombin-heparin composition SERPINC1, HPSE, PLAT CYP2D6 1611/4885TSHR 357/4885CA9 801/4885
US-20190030066-A1 ANTITHROMBIN-HEPARIN COMPOSITIONS AND METHODS SERPINC1, HPSE, SERPINA3 CYP2D6 3679/4885TSHR 686/4885CA9 934/4885
US-20170020911-A1 ANTITHROMBIN-HEPARIN COMPOSITIONS AND METHODS SERPINC1, HPSE, SERPINA3 CYP2D6 3679/4885TSHR 686/4885CA9 934/4885
US-20180177924-A1 Medical Devices, Systems, and Methods Utilizing Antithrombin-Heparin Composition SERPINC1, HPSE, PLAT CYP2D6 1611/4885TSHR 357/4885CA9 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.